Cadrenal Therapeutics, Inc., a biotech company operating within the health care sector, has been making strides in the development of tecarfarin, a novel therapy with an orphan drug indication. Tecarfarin is specifically designed to prevent systemic thromboembolism (blood clots) of cardiac origin in patients suffering from end-stage renal disease (ESRD) and atrial fibrillation. This innovative approach positions Cadrenal Therapeutics as a significant player in addressing critical health challenges associated with these conditions.
The company, which is publicly traded on the Nasdaq stock exchange, has been active since its initial public offering (IPO) on January 19, 2023. As of March 17, 2026, Cadrenal Therapeutics’ shares were trading at a close price of $7.24. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $19.96 on March 24, 2025, and a 52-week low of $4.91 on February 16, 2026. These movements reflect the dynamic nature of the biotech sector and investor sentiment towards the company’s developmental progress and market potential.
With a market capitalization of approximately $16,296,745 USD, Cadrenal Therapeutics is navigating the competitive landscape of the health care industry. The company’s financial metrics, including a price-to-earnings (P/E) ratio of -0.891, indicate that it is currently not generating profits, which is not uncommon for biotech firms in the early stages of drug development. Investors and stakeholders are likely focused on the company’s pipeline and the potential market impact of tecarfarin.
Cadrenal Therapeutics serves a global customer base, offering its innovative solutions to patients worldwide. The company maintains an online presence through its website, www.cadrenal.com , where it provides information about its products, research initiatives, and corporate developments.
As Cadrenal Therapeutics continues to advance its research and development efforts, the biotech community and healthcare professionals are closely monitoring its progress. The successful development and commercialization of tecarfarin could significantly impact the treatment landscape for patients with ESRD and atrial fibrillation, potentially reducing the incidence of life-threatening thromboembolic events. The company’s commitment to innovation and patient care remains central to its mission as it navigates the challenges and opportunities within the health care sector.
